PI: Robert Clark, MD
Funding: National Institute of Neurologic Diseases and Stroke R01NS069247 (7/1/2009 – 6/30/2015)
There is a sense of urgency to move forward with pharmacological therapies that improve outcome after brain injury. This project tests combinational strategies that overcome membrane transport barriers to synergistically improve bioavailability and efficacy of both clinically used and novel therapies after traumatic brain injury. We aim to define the capacity of the combination of probenecid and N-acetylcysteine (NAC) to synergistically reduce oxidative stress and improve neurological outcome in experimental models, and to define the capacity of the combination of probenecid and NAC to safely and synergistically reduce oxidative stress in children (Phase I/II Pro-NAC trial), after traumatic brain injury.
See results of this project at the NIH RePORTER